Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

46
Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders Chapter 31

description

Chapter 31. Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders. Hepatic Functions. Macronutrient metabolism CHO: glycogenesis, glycogenolysis, gluconeogenesis, converts fructose & galactose to glucose, breaks down glucose for energy as needed - PowerPoint PPT Presentation

Transcript of Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

Page 1: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

Chapter 31Chapter 31

Page 2: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Hepatic FunctionsHepatic Functions

Macronutrient metabolism

– CHO: glycogenesis, glycogenolysis, gluconeogenesis, converts fructose & galactose to glucose, breaks down glucose for energy as needed

– Lipids: builds/breaks down TG, phospholipids, and Chol as needed, breaks down FA for energy, packages extra lipids in lipoproteins for transport to other body organs, manufactures bile and ketones when necessary

Macronutrient metabolism

– CHO: glycogenesis, glycogenolysis, gluconeogenesis, converts fructose & galactose to glucose, breaks down glucose for energy as needed

– Lipids: builds/breaks down TG, phospholipids, and Chol as needed, breaks down FA for energy, packages extra lipids in lipoproteins for transport to other body organs, manufactures bile and ketones when necessary

Page 3: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Hepatic Functions Hepatic Functions

Proteins: manufactures nonessential AA when needed, removes excess AA, removes ammonia and converts it to urea, makes other nitrogen-containing compounds the body needs, makes plasma proteins such as clotting factors

Other: detoxifies alcohol, drugs & poisons, helps dismantle old RBCs & recycles Fe, stores most vit/min’s, forms lymph, provides filter/flood chamber

Proteins: manufactures nonessential AA when needed, removes excess AA, removes ammonia and converts it to urea, makes other nitrogen-containing compounds the body needs, makes plasma proteins such as clotting factors

Other: detoxifies alcohol, drugs & poisons, helps dismantle old RBCs & recycles Fe, stores most vit/min’s, forms lymph, provides filter/flood chamber

Page 4: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Common Laboratory Tests Used to Test for Liver FunctionCommon Laboratory Tests Used to Test for Liver Function

Hepatic excretion

—Total serum bilirubin, urine bilirubin

Cholestasis tests

—Serum alkaline phosphatase

Hepatic enzymes

—ALT, AST

Hepatic excretion

—Total serum bilirubin, urine bilirubin

Cholestasis tests

—Serum alkaline phosphatase

Hepatic enzymes

—ALT, AST

Page 5: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Common Laboratory Tests Used to Test for Liver Function—cont’dCommon Laboratory Tests Used to Test for Liver Function—cont’d

Serum proteins

—PT, PTT, serum albumin

Markers of specific liver diseases

—Serum ferritin, ceruloplasmin

Specific tests for viral hepatitis

—IgM anti-HAV, anti-HBS, HCV-RNA

Serum proteins

—PT, PTT, serum albumin

Markers of specific liver diseases

—Serum ferritin, ceruloplasmin

Specific tests for viral hepatitis

—IgM anti-HAV, anti-HBS, HCV-RNA

Page 6: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Diseases of the LiverDiseases of the Liver

Acute viral hepatitis

Fulminant hepatitis

Chronic hepatitis

Alcoholic liver disease, alcoholic hepatitis, and cirrhosis

Acute viral hepatitis

Fulminant hepatitis

Chronic hepatitis

Alcoholic liver disease, alcoholic hepatitis, and cirrhosis

Page 7: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Diseases of the Liver—cont’dDiseases of the Liver—cont’d

Cholestatic liver diseases

—Primary biliary cirrhosis

—Sclerosing cholangitis

Inherited disorders

Other liver diseases

Cholestatic liver diseases

—Primary biliary cirrhosis

—Sclerosing cholangitis

Inherited disorders

Other liver diseases

Page 8: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Acute Viral HepatitisAcute Viral Hepatitis

Widespread inflammation of the liver that is caused by hepatitis viruses A, B, C, D, and E

Four phases of symptoms:

1. Prodromal phase

2. Preicteric phase

3. Icteric phase

4. Convalescent phase

Widespread inflammation of the liver that is caused by hepatitis viruses A, B, C, D, and E

Four phases of symptoms:

1. Prodromal phase

2. Preicteric phase

3. Icteric phase

4. Convalescent phase

Page 9: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Fulminant HepatitisFulminant Hepatitis

Syndrome in which severe liver dysfunction is accompanied by hepatic encephalopathy

Syndrome in which severe liver dysfunction is accompanied by hepatic encephalopathy

Page 10: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Chronic HepatitisChronic Hepatitis

At least 6-month course of hepatitis or biochemical and clinical evidence of liver disease with confirmatory biopsy findings of unresolving hepatic inflammation

At least 6-month course of hepatitis or biochemical and clinical evidence of liver disease with confirmatory biopsy findings of unresolving hepatic inflammation

Page 11: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Most Common Liver DiseaseMost Common Liver Disease

Alcohol excess and abuse

Fourth leading cause of death among middle-aged Americans

Alcohol problems are highest among young adults, ages 18 to 29.

Alcohol excess and abuse

Fourth leading cause of death among middle-aged Americans

Alcohol problems are highest among young adults, ages 18 to 29.

Page 12: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Alcoholic Liver DiseaseAlcoholic Liver Disease

Disease resulting from excessive alcohol ingestion characterized by fatty liver (hepatic steatosis), hepatitis, or cirrhosis

Disease resulting from excessive alcohol ingestion characterized by fatty liver (hepatic steatosis), hepatitis, or cirrhosis

Page 13: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Complications of Excessive Alcohol Consumption Stem Largely from Excess Hydrogen and from AcetaldehydeComplications of Excessive Alcohol Consumption Stem Largely from Excess Hydrogen and from Acetaldehyde

Page 14: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Alcoholic Liver DiseaseMetabolic ChangesAlcoholic Liver DiseaseMetabolic Changes

Steatorrhea

Wernicke-Korsakoff syndrome

Peripheral neuropathy

Pellagrous psychosis

Folate deficiency

Steatorrhea

Wernicke-Korsakoff syndrome

Peripheral neuropathy

Pellagrous psychosis

Folate deficiency

Page 15: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

End-Stage Alcoholic Liver DiseasePossible CharacteristicsEnd-Stage Alcoholic Liver DiseasePossible Characteristics

Malnutrition

Portal hypertension with varices

Ascites

Hyponatremia

Hepatic encephalopathy

Glucose alterations

Malnutrition

Portal hypertension with varices

Ascites

Hyponatremia

Hepatic encephalopathy

Glucose alterations

Page 16: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

End-Stage Alcoholic Liver DiseasePossible Characteristics—cont’dEnd-Stage Alcoholic Liver DiseasePossible Characteristics—cont’d

Fat malabsorption

Osteopenia

Thrombocytopenia with anemia

Fat malabsorption

Osteopenia

Thrombocytopenia with anemia

Page 17: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Cholestatic Liver DiseasesCholestatic Liver Diseases

Primary biliary cirrhosis (PBC)

—An immune-mediated chronic cirrhosis of the liver due to obstruction or infection of the small and intermediate-sized intrahepatic bile ducts, whereas the extrahepatic biliary tree and larger intrahepatic ducts are normal

—90% of patients are women

Primary biliary cirrhosis (PBC)

—An immune-mediated chronic cirrhosis of the liver due to obstruction or infection of the small and intermediate-sized intrahepatic bile ducts, whereas the extrahepatic biliary tree and larger intrahepatic ducts are normal

—90% of patients are women

Page 18: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Cholestatic Liver Diseases—cont’dCholestatic Liver Diseases—cont’d

Sclerosing cholangitis

—Fibrosing inflammation of segments of extrahepatic bile ducts, with or without involvement of intrahepatic ducts

Sclerosing cholangitis

—Fibrosing inflammation of segments of extrahepatic bile ducts, with or without involvement of intrahepatic ducts

Page 19: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Inherited DisordersInherited Disorders

Hemochromatosis

—Inherited disease of iron overload

Wilson’s disease

—Autosomal recessive disorder associated with impaired biliary copper excretion

α1-antitrypsin deficiency

—Causes cholestasis or cirrhosis and can cause liver and lung cancer

Hemochromatosis

—Inherited disease of iron overload

Wilson’s disease

—Autosomal recessive disorder associated with impaired biliary copper excretion

α1-antitrypsin deficiency

—Causes cholestasis or cirrhosis and can cause liver and lung cancer

Page 20: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Other Liver DiseasesOther Liver Diseases

Several other causes of liver disease, including

—Liver tumors

—Systemic diseases (rheumatoid arthritis, systemic sclerosis)

—Nonalcoholic steatohepatitis

—Acute ischemic and chronic congestive hepatopathy

—Parasitic, bacterial, fungal, and granulomatous liver diseases

Several other causes of liver disease, including

—Liver tumors

—Systemic diseases (rheumatoid arthritis, systemic sclerosis)

—Nonalcoholic steatohepatitis

—Acute ischemic and chronic congestive hepatopathy

—Parasitic, bacterial, fungal, and granulomatous liver diseases

Page 21: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Normal Liver vs. Damaged LiverNormal Liver vs. Damaged Liver

Page 22: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Microscopic Appearance of (A) a Normal Liver and (B) Acute Fatty LiverMicroscopic Appearance of (A) a Normal Liver and (B) Acute Fatty Liver

(Adapted from Bray GA. Gray DS, Obesity, part 1: Pathogenisis. West J Med 149:429, 1988; and Lew EA, Garfinkle L; Variations in mortality by weight among 750,000 men and women. J Clin Epidemiol 32:563, 1979.)(From Kanel G, Korula J. Atlas of Liver Pathology. W.B. Saunders, 1992.)

Page 23: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Clinical Manifestations of CirrhosisClinical Manifestations of Cirrhosis

Page 24: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Clinical Manifestations of CirrhosisClinical Manifestations of Cirrhosis

Page 25: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Factors That Affect Interpretation of Objective Nutrition Assessment Tests in Patients with End-Stage Liver Disease

Factors That Affect Interpretation of Objective Nutrition Assessment Tests in Patients with End-Stage Liver Disease

Body weight

Anthropometric measurements

Creatinine-height index

Nitrogen balance studies

Body weight

Anthropometric measurements

Creatinine-height index

Nitrogen balance studies

3-methylhistidine excretion

Visceral protein levels

Immune function tests

3-methylhistidine excretion

Visceral protein levels

Immune function tests

Page 26: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

SGA Parameters for Nutritional Evaluation of Liver Disease PatientsSGA Parameters for Nutritional Evaluation of Liver Disease Patients

History –wt changes/fluctuations,diet, appetite, taste changes, early satiety, GI problems

Physical- muscle wasting, fat stores, fluid status(edema/ascites)

Existing conditions-disease state/other problems that may affect nutritional status

Nutritional rating (based on results of above parameters)

History –wt changes/fluctuations,diet, appetite, taste changes, early satiety, GI problems

Physical- muscle wasting, fat stores, fluid status(edema/ascites)

Existing conditions-disease state/other problems that may affect nutritional status

Nutritional rating (based on results of above parameters)

Page 27: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Severe Malnutrition and Ascites in a Man with End-Stage Liver DiseaseSevere Malnutrition and Ascites in a Man with End-Stage Liver Disease

Page 28: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Malnutrition in Liver Disease—CauseMalnutrition in Liver Disease—Cause

Algorithm content developed by John Anderson, PhD, and Sanford C. Garner, PhD, 2000. Updated by Jeanette M. Hasse and Laura E. Matarese, 2002.

Page 29: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Malnutrition in Liver Disease—PathophysiologyMalnutrition in Liver Disease—Pathophysiology

Algorithm content developed by John Anderson, PhD, and Sanford C. Garner, PhD, 2000. Updated by Jeanette M. Hasse and Laura E. Matarese, 2002.

Page 30: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Malnutrition in Liver Disease—Medical and Nutritional ManagementMalnutrition in Liver Disease—Medical and Nutritional Management

Algorithm content developed by John Anderson, PhD, and Sanford C. Garner, PhD, 2000. Updated by Jeanette M. Hasse and Laura E. Matarese, 2002.

Page 31: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Vitamin/Mineral Deficits in Severe Hepatic FailureVitamin/Mineral Deficits in Severe Hepatic Failure

Vitamin A

Vitamin D

Vitamin E

Vitamin K

Vitamin B6

Vitamin B12

Folate

Vitamin A

Vitamin D

Vitamin E

Vitamin K

Vitamin B6

Vitamin B12

Folate

Niacin

Thiamin

Zinc

Magnesium

Iron

Potassium

Phosphorus

Niacin

Thiamin

Zinc

Magnesium

Iron

Potassium

Phosphorus

Page 32: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Four Stages of Hepatic EncephalopathyFour Stages of Hepatic Encephalopathy

Stage Symptom

I Mild confusion, agitation, irritability, sleep disturbance, decreased attention

II Lethargy, disorientation, inappropriate behavior, drowsiness

III Somnolence but arousable, incomprehensible speech, confusion, aggression when awake

IV Coma

Stage Symptom

I Mild confusion, agitation, irritability, sleep disturbance, decreased attention

II Lethargy, disorientation, inappropriate behavior, drowsiness

III Somnolence but arousable, incomprehensible speech, confusion, aggression when awake

IV Coma

Page 33: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

End-Stage Liver DiseaseHepatic EncephalopathyEnd-Stage Liver DiseaseHepatic Encephalopathy

1. Consider major causes of encephalopathy

• GI bleeding

• Fluid and electrolyte abnormalities

• Uremia

• Use of sedatives

• Hypo- or hyperglycemia

• Alcohol withdrawal

• Constipation

• Acidosis

1. Consider major causes of encephalopathy

• GI bleeding

• Fluid and electrolyte abnormalities

• Uremia

• Use of sedatives

• Hypo- or hyperglycemia

• Alcohol withdrawal

• Constipation

• Acidosis

Page 34: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

End-Stage Liver DiseaseHepatic Encephalopathy—cont’dEnd-Stage Liver DiseaseHepatic Encephalopathy—cont’d

2. Treat underlying cause.

3. Treat with medications.

• Lactulose

• Neomycin

4. Ensure adequate diet is consumed.

2. Treat underlying cause.

3. Treat with medications.

• Lactulose

• Neomycin

4. Ensure adequate diet is consumed.

Page 35: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

End-Stage Liver Disease End-Stage Liver Disease

Energy: 30 to 35 kcal/kg dry weight

BEE x 1.2 to 1.5, depending on degree of malnutrition

Fat: 25% to 40% of kcal

May try MCT if steatorrhea is present; with severe case, try fat restriction and discontinue if diarrhea does not improve

Protein: 1to 1.5 g/kg dry wt depending on degree of malnutrition, malabsorption, metabolic stress

Energy: 30 to 35 kcal/kg dry weight

BEE x 1.2 to 1.5, depending on degree of malnutrition

Fat: 25% to 40% of kcal

May try MCT if steatorrhea is present; with severe case, try fat restriction and discontinue if diarrhea does not improve

Protein: 1to 1.5 g/kg dry wt depending on degree of malnutrition, malabsorption, metabolic stress

Page 36: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

End-Stage Liver Disease—cont’dEnd-Stage Liver Disease—cont’d

May try BCAA formulas for >grade 2 encephalopathy

CHO: high intake of both complex and simple carbohydrates

Vitamin and mineral supplements

Electrolytes: restrict sodium with edema or ascites (2-4 g/day)

Fluid: restrict fluid if hyponatremia is present

May try BCAA formulas for >grade 2 encephalopathy

CHO: high intake of both complex and simple carbohydrates

Vitamin and mineral supplements

Electrolytes: restrict sodium with edema or ascites (2-4 g/day)

Fluid: restrict fluid if hyponatremia is present

Page 37: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Amino Acids Commonly Altered in Liver DiseaseAmino Acids Commonly Altered in Liver Disease

Aromatic amino acids—serum levels increased

—Tyrosine

—Phenylalanine*

—Free tryptophan* Branched-chain amino acids—serum levels decreased

—Valine*

—Leucine*

—Isoleucine* Other amino acids—serum levels increased

—Methionine*

—Glutamine

Aromatic amino acids—serum levels increased

—Tyrosine

—Phenylalanine*

—Free tryptophan* Branched-chain amino acids—serum levels decreased

—Valine*

—Leucine*

—Isoleucine* Other amino acids—serum levels increased

—Methionine*

—Glutamine

—Asparagine—Histidine*

—Asparagine—Histidine*

* Denotes essentials amino acids* Denotes essentials amino acids

Page 38: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

SummarySummary

Liver disorders—role of liver is so crucial to overall health, its destruction is quite serious

Goals—support maintenance of as much normal liver function as possible

Transplantation, if needed

Liver disorders—role of liver is so crucial to overall health, its destruction is quite serious

Goals—support maintenance of as much normal liver function as possible

Transplantation, if needed

Page 39: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Medications Commonly Used after Liver TransplantationMedications Commonly Used after Liver Transplantation

Azathioprine

Antithymocyte globulin

Basiliximab

Cyclosporine

Daclizumab

Glucocorticoids

Azathioprine

Antithymocyte globulin

Basiliximab

Cyclosporine

Daclizumab

Glucocorticoids

Muromonab-CD3

Mycophenolate mofetil

Sirolimus

Tacrolimus

15-deoxysperagualin

Muromonab-CD3

Mycophenolate mofetil

Sirolimus

Tacrolimus

15-deoxysperagualin

Page 40: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Nutrition Care Guidelines for Liver TransplantationNutrition Care Guidelines for Liver Transplantation

Pretransplantation

Immediate posttransplantation

Long-term posttransplantation

Pretransplantation

Immediate posttransplantation

Long-term posttransplantation

Calories

Protein

Fat

Carbohydrate

Sodium

Fluid

Calcium

Vitamins

Calories

Protein

Fat

Carbohydrate

Sodium

Fluid

Calcium

Vitamins

Page 41: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Liver Transplantation—DietLiver Transplantation—Diet

Nutrition support: pre- and posttransplant

Long-term preventive nutrition to optimize health and to avoid or minimize

—Excessive weight gain

—Hyperlipidemia

—Hyperglycemia

—Hypertension

—Osteopenia

Nutrition support: pre- and posttransplant

Long-term preventive nutrition to optimize health and to avoid or minimize

—Excessive weight gain

—Hyperlipidemia

—Hyperglycemia

—Hypertension

—Osteopenia

Page 42: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Relationship of Organs of the Upper AbdomenRelationship of Organs of the Upper Abdomen

A, Liver (retracted upward); B, gallbladder; C, esophageal opening of the stomach; D, stomach (shown in dotted outline); E, common bile duct; F, duodenum; G, pancreas and pancreatic duct; H, spleen; I, kidneys.

Courtesy The Cleveland Clinic Foundation, Cleveland, Ohio, 2002.

Page 43: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Some Tests of Pancreatic FunctionSome Tests of Pancreatic Function

Page 44: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Pancreatic Disorders—CausePancreatic Disorders—Cause

Algorithm content developed by John Anderson, PhD, and Sanford C. Garner, PhD, 2000.

Page 45: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Pancreatic Disorders—PathophysiologyPancreatic Disorders—Pathophysiology

Algorithm content developed by John Anderson, PhD, and Sanford C. Garner, PhD, 2000.

Page 46: Medical Nutrition Therapy for Liver, Biliary System, and Exocrine Pancreas Disorders

© 2004, 2002 Elsevier Inc. All rights reserved.

Pancreatic Disorders—Medical and Nutritional ManagementPancreatic Disorders—Medical and Nutritional Management

Algorithm content developed by John Anderson, PhD, and Sanford C. Garner, PhD, 2000. Updated by Jeanette M. Hasse and Laura E. Matarese, 2002.